Study guide
14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
Key Takeaways Explain This Topic AI
Alcohol is a Group 1 human carcinogen causally linked to cancers of the oral cavity, pharynx, larynx, esophagus, liver, colorectum and female breast.
Breast cancer risk rises measurably at roughly one drink per day, making it the cancer risk most relevant to moderate-drinking women.
Only about 16% of Wernicke encephalopathy patients show the full triad, so the Caine criteria (any two of four features) should trigger empiric high-dose parenteral thiamine.
Refeeding syndrome, hypomagnesemia and hypophosphatemia are common in malnourished drinkers and must be corrected before or alongside nutritional repletion.
The January 2025 U.S. Surgeon General's Advisory names alcohol the third leading preventable cause of cancer in the United States, behind tobacco use and obesity.
Last updated: September 2026
14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
Quick Answer: Alcohol is a Group 1 carcinogen causally linked to cancers of the oral cavity, pharynx, larynx, esophagus, liver, colorectum and female breast ; breast cancer risk is detectable at about one drink per day . Cardiac effects include dose-dependent dilated cardiomyopathy (often partly reversible with abstinence), holiday heart syndrome (binge-associated atrial fibrillation), and dose-dependent hypertension . Nutritional consequences center on thiamine , folate , magnesium , phosphate , zinc and vitamin D , with refeeding syndrome as the main hazard of repletion.
Most CARN-AP candidates are comfortable with liver disease and withdrawal but under-prepared on the rest of alcohol's medical footprint. The exam's alcohol patient-problem area carries 24% of the items , and a large share of those items sit in the screen/assess/diagnose and educate activity areas — meaning you are far more likely to be asked what to counsel, what to order, and what to correct first than to be asked a pure pathophysiology question. This section organizes the non-hepatic consequences the way an advanced practice nurse actually uses them: what to say to the patient, what to monitor, and what sequence of interventions is safe.
1. Cancer: What to Actually Tell Patients
Ethanol is metabolized to acetaldehyde , a direct DNA-adduct-forming carcinogen. People with the ALDH2*2 variant (common in East Asian populations) accumulate acetaldehyde, producing the flushing reaction and markedly elevated esophageal cancer risk with continued drinking.
- Site Relationship
- Oral cavity, pharynx, larynx, esophagus (squamous) Strong dose-response; multiplicative with tobacco
- Liver Mediated largely through cirrhosis
- Colorectum Modest but consistent dose-response
- Female breast Detectable increase at about one drink per day; mediated partly through estrogen
- Putting a number on the risk
The U.S. Surgeon General's Advisory on Alcohol and Cancer Risk , issued January 3, 2025 , is the citation to know. It identifies alcohol as the third leading preventable cause of cancer in the United States , behind tobacco use and obesity, and attributes roughly 100,000 cancer cases and about 20,000 cancer deaths in the United States each year to alcohol. It names the same seven cancer sites listed above and calls for updated warning labels, routine clinical counseling about the alcohol-cancer link, and expanded use of screening with brief intervention and referral to treatment. That last recommendation matters for scope: the advisory explicitly frames SBIRT as the clinical response to alcohol-attributable cancer, which is exactly the APRN activity the blueprint tests.
The advisory also documents that public awareness is low. Most patients believe alcohol-cancer risk begins only at heavy, visible drinking, and many believe wine is protective. Correcting that belief is itself a billable, evidence-based intervention, and it frequently lands with patients who have dismissed liver-based arguments because their liver enzymes are normal.
Teaching frame that works: "There is no amount of alcohol that has been shown to lower cancer risk. Cutting back lowers it, and stopping lowers it more. For breast cancer, the risk starts climbing at about one drink a day — which surprises most people."
Two counseling refinements are worth rehearsing. First, risk is reversible in direction but not instantly : upper aerodigestive cancer risk falls after cessation but takes years to approach never-drinker levels, so frame the benefit as long-term rather than immediate. Second, avoid absolute-risk inflation . A patient who hears "alcohol causes breast cancer" and interprets it as a near-certainty may disengage entirely; give the relative framing honestly and pair it with the other modifiable risks she controls.
2. Cardiovascular Effects
Hypertension. Dose-dependent; reducing intake lowers blood pressure measurably within weeks, making this one of the fastest visible wins the APRN can offer.
Alcohol-induced cardiomyopathy. A dilated cardiomyopathy from cumulative exposure. The commonly cited exposure threshold is more than about 80 g of ethanol per day (roughly six standard drinks) sustained for five or more years , though the literature treats that figure as approximate rather than diagnostic. Ejection fraction frequently improves — sometimes substantially — with sustained abstinence plus guideline-directed medical therapy.
Holiday heart syndrome. Atrial fibrillation or flutter precipitated by a binge, classically in a person without structural heart disease. The term comes from Ettinger's 1978 case series , which described supraventricular tachyarrhythmias clustering around weekends and holidays and resolving with abstinence. It often converts spontaneously within 24 hours. The teaching point is that even people who rarely drink can trigger it, and that recurrent episodes predict persistent atrial fibrillation.
Stroke. Heavy drinking increases both ischemic and hemorrhagic stroke risk.
Abstinence as antiarrhythmic therapy
The strongest evidence an APRN can quote to a drinker with atrial fibrillation is the 2020 randomized trial of alcohol abstinence in regular drinkers with AF (140 patients averaging about 17 drinks per week). Patients randomized to abstinence had AF recurrence in 53% versus 73% in the control group, and recurrence took longer to occur. This reframes the conversation from moralizing to prescribing: alcohol reduction is a rhythm-control intervention with a randomized-trial effect size, comparable in magnitude to interventions cardiology accepts without argument.
Practical monitoring for the APRN: obtain an ECG in any heavy drinker with palpitations or syncope, and order an echocardiogram when there is dyspnea, edema, an S3, or an unexplained tachycardia — alcohol-induced cardiomyopathy is frequently silent until decompensation. Check a potassium and magnesium before attributing an arrhythmia to alcohol alone, because electrolyte depletion in this population is both common and independently arrhythmogenic. Document the drinking quantity in standard drinks per week , not "social," so that change over time is measurable.
3. Pancreatic and Gastrointestinal Effects
Condition Notes
Acute pancreatitis Alcohol is a leading cause; presents with epigastric pain radiating to the back, elevated lipase
Chronic pancreatitis Produces exocrine insufficiency (steatorrhea, fat-soluble vitamin deficiency), endocrine insufficiency (type 3c diabetes), and chronic pain that intersects dangerously with opioid prescribing
- Gastritis and peptic ulcer Direct mucosal injury plus NSAID co-use
- Mallory-Weiss tear Longitudinal mucosal tear at the gastroesophageal junction after forceful retching
- Variceal hemorrhage Portal hypertension complication; a medical emergency
Chronic pancreatitis deserves particular attention in addictions practice because it generates genuine, severe, ongoing nociceptive pain in a patient with an active substance use disorder . The reflex to withhold all analgesia is as harmful as reflexive opioid prescribing. Treat exocrine insufficiency with pancreatic enzyme replacement, use non-opioid multimodal analgesia first, coordinate with gastroenterology on interventional options, and if opioids are used, use them inside a documented plan with a single prescriber, PDMP review, and explicit function-based goals.
4. Micronutrient Deficiencies and the Order of Repletion
Nutrient Why deficient Consequence APRN action
Thiamine (B1) Poor intake, impaired jejunal absorption, reduced hepatic storage, impaired conversion to thiamine pyrophosphate Wernicke encephalopathy, Korsakoff syndrome, wet beriberi Parenteral thiamine before any glucose load
Magnesium Renal wasting, GI losses Refractory hypokalemia and hypocalcemia; arrhythmia; lowers seizure threshold Replete magnesium first — potassium and calcium will not correct without it, and thiamine-dependent enzymes require magnesium as a cofactor
Folate Poor intake, impaired absorption Macrocytic anemia Oral folate
Phosphate Shifts intracellularly during refeeding Rhabdomyolysis, respiratory muscle failure, hemolysis Monitor daily during repletion
Zinc Poor intake, urinary loss Impaired wound healing, dysgeusia, night blindness, immune dysfunction Supplement in chronic liver disease
- Vitamin D and calcium Poor intake, malabsorption, liver disease Osteoporosis, fracture Screen and supplement
- Refeeding syndrome
In a severely malnourished drinker, reintroduction of carbohydrate drives insulin release, which shifts phosphate, potassium and magnesium intracellularly. The result can be cardiac arrhythmia, respiratory failure and death. Management: start nutrition at reduced caloric load , give thiamine before and during repletion, check electrolytes at least daily for the first several days, and correct deficits before advancing calories.
Exam trap: the classic error is giving intravenous dextrose to a hypoglycemic, malnourished drinker before thiamine. Glucose consumes the remaining thiamine as a cofactor in glycolysis and can precipitate Wernicke encephalopathy. Thiamine goes first, or at minimum simultaneously.
5. Wernicke-Korsakoff Spectrum: Recognize It, Then Dose It Properly
Thiamine deficiency is the one nutritional problem on this list that kills within days, and the exam tests it as a recognition-plus-dosing problem rather than a definition.
Recognition. The classic triad is encephalopathy, oculomotor dysfunction (nystagmus, ophthalmoplegia) and gait ataxia — but only about 16% of patients present with all three , and roughly 19% have none of the classic features at first evaluation. Waiting for the triad is how the diagnosis is missed. Use the Caine criteria instead, which require two of four : dietary deficiency, oculomotor abnormalities, cerebellar dysfunction, or either altered mental status or mild memory impairment. Applied this way the criteria are roughly 85% sensitive .
Stakes. Untreated Wernicke encephalopathy carries an estimated 17% mortality , and among survivors about 80% go on to develop Korsakoff syndrome — the persistent anterograde amnesia, disorientation to time and confabulation that ends independent living for many patients. Korsakoff is largely irreversible; Wernicke is largely preventable. That asymmetry is the entire argument for empiric treatment.
Dosing. Doses used for prophylaxis are not adequate for treatment, and this is the most common exam discriminator:
Scenario Regimen
Suspected or confirmed Wernicke encephalopathy Royal College guidance: thiamine 500 mg IV every 8 hours for 3 days , then 250 mg IV/IM daily until improvement plateaus, often a further 3-5 days. The European Federation guideline uses 200 mg IV every 8 hours until no further improvement is seen.
- At-risk drinker, no neurologic signs Parenteral thiamine on presentation, then oral maintenance
- Any glucose administration in a drinker Thiamine before or simultaneously with dextrose
Two practical notes. Oral thiamine is unreliable in active heavy drinkers because alcohol impairs jejunal absorption, so the route matters as much as the dose. And magnesium must be repleted alongside thiamine , because thiamine-dependent enzymes require magnesium as a cofactor — a thiamine-replete, magnesium-depleted patient can still fail to improve.
6. Working the Whole Picture in One Encounter
A 52-year-old man presents after three days without alcohol: drinking roughly 14 standard drinks daily for 20 years, BMI 18, potassium 2.8, magnesium 1.2, phosphate 2.0, glucose 58, unsteady gait and inattention. The correct sequence is not a judgment call; it is an order of operations. Give parenteral thiamine first , then treat hypoglycemia. Replete magnesium before chasing potassium. Initiate nutrition at reduced caloric load with daily electrolytes because he meets refeeding criteria. Manage withdrawal on a symptom-triggered protocol. Obtain an ECG given the electrolyte picture and the drinking history, and an echocardiogram if there is any dyspnea or edema. Before discharge, start medication for alcohol use disorder , and use the visit to deliver the cancer-risk counseling the Surgeon General's advisory recommends — because this encounter, not a future one, is where his engagement is highest.